Sean A. McCarthy - 20 Sep 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
CEO, Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
Issuer symbol
CTMX
Transactions as of
20 Sep 2023
Net transactions value
-$18,987
Form type
4
Filing time
22 Sep 2023, 19:13:47 UTC
Previous filing
23 May 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +40,000 +9.9% $0.000000 445,356 20 Sep 2023 Direct F1, F2
transaction CTMX Common Stock Sale $18,987 -14,601 -3.3% $1.30 430,755 22 Sep 2023 Direct F2, F3
holding CTMX Common Stock 93,158 20 Sep 2023 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
F2 Includes 161,250 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
F4 Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.